Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patisiran in ATTR Amyloidosis with Cardiomyopathy
2023-508364-29-00Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2024
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR), hereditary transthyretin amyloidosis (hATTR) and acquired transthyretin amyloidosis (ATTRwt) comparing Patisiran (Onpattro) with Placebo (2 arms). Primary endpoint: Change from baseline at Month 12 in 6-minute walk test (6-MWT) distance. Started Nov 2024; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)hereditary transthyretin amyloidosis (hATTR)acquired transthyretin amyloidosis (ATTRwt)
Beyond the preview
Go deeper on 2023-508364-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508364-29-00.